NASDAQ:SPNC - Spectranetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$38.45 0.00 (0.00 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$38.45
Today's Range$38.45 - $38.45
52-Week Range$19.80 - $38.55
VolumeN/A
Average Volume788,356 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Spectranetics logoThe Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads. Its geographic segments are U.S. Medical and International Medical. Its product offerings in U.S. Medical segment include medical devices used in minimally invasive procedures within the cardiovascular system, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment) and the service of the excimer laser system (service). Its products are used in multiple vascular procedures, including peripheral atherectomy, crossing arterial blockages, coronary atherectomy and thrombectomy. Its International Medical segment is primarily engaged in distribution activities.

Receive SPNC News and Ratings via Email

Sign-up to receive the latest news and ratings for SPNC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNASDAQ:SPNC
CUSIP84760C10
Phone+1-719-6338333

Debt

Debt-to-Equity Ratio7.61
Current Ratio1.92
Quick Ratio1.43

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-32.93%
Return on Equity-194.18%
Return on Assets-23.25%

Miscellaneous

Employees960
Outstanding Shares43,850,000

Spectranetics (NASDAQ:SPNC) Frequently Asked Questions

What is Spectranetics' stock symbol?

Spectranetics trades on the NASDAQ under the ticker symbol "SPNC."

How were Spectranetics' earnings last quarter?

Spectranetics Corp (NASDAQ:SPNC) released its quarterly earnings results on Thursday, August, 3rd. The medical equipment provider reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.29. The medical equipment provider had revenue of $74.71 million for the quarter, compared to the consensus estimate of $73.82 million. Spectranetics had a negative net margin of 32.93% and a negative return on equity of 194.18%. Spectranetics's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.35) EPS. View Spectranetics' Earnings History.

What price target have analysts set for SPNC?

9 analysts have issued 12-month price objectives for Spectranetics' stock. Their predictions range from $27.00 to $38.50. On average, they anticipate Spectranetics' stock price to reach $35.3571 in the next twelve months. View Analyst Ratings for Spectranetics.

Who are Spectranetics' key executives?

Spectranetics' management team includes the folowing people:
  • B. Kristine Johnson, Chairman of the Board (Age 65)
  • Scott William Drake, President, Chief Executive Officer, Director (Age 49)
  • Stacy McMahan, Chief Financial Officer (Age 53)
  • Shahriar Matin, Chief Operating Officer (Age 42)
  • Scott Hutton, Senior Vice President and General Manager of Vascular Intervention (Age 45)
  • Donna Ford-Serbu, Senior Vice President - Sales and Marketing of Lead Management (Age 48)
  • William C. Jennings, Independent Director (Age 78)
  • Daniel A. Pelak, Independent Director (Age 65)
  • Joseph M. Ruggio M.D., Independent Director (Age 62)
  • Maria Degois Sainz, Independent Director (Age 51)

Has Spectranetics been receiving favorable news coverage?

Media headlines about SPNC stock have trended positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Spectranetics earned a daily sentiment score of 0.27 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 44.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Spectranetics?

Shares of SPNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectranetics' stock price today?

One share of SPNC stock can currently be purchased for approximately $38.45.

How big of a company is Spectranetics?

Spectranetics has a market capitalization of $1.68 billion. Spectranetics employs 960 workers across the globe.

How can I contact Spectranetics?

Spectranetics' mailing address is 9965 Federal Dr, COLORADO SPRINGS, CO 80921-3822, United States. The medical equipment provider can be reached via phone at +1-719-6338333.


MarketBeat Community Rating for Spectranetics (SPNC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Spectranetics and other stocks. Vote "Outperform" if you believe SPNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.